We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AstraZeneca plc (AZN) ADR Each Representing 0.5 Ord Shares

Sell:$65.92 Buy:$65.95 Change: $0.12 (0.18%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.12 (0.18%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.12 (0.18%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Contact details

1 Francis Crick Avenue
United Kingdom
+44 (20) 73045000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$207.68 billion
Shares in issue:
1.55 billion
United States
US dollar

Key personnel

  • Pascal Soriot
    Chief Executive Officer, Executive Director
  • Aradhana Sarin
    Chief Financial Officer, Executive Director
  • Marc Dunoyer
    Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
  • Jeffrey Pott
    Chief Human Resource Officer, General Counsel
  • Katarina Ageborg
    Executive Vice President - Sustainability, Chief Compliance Officer
  • Pam Cheng
    Executive Vice President - Operations and Information Technology
  • Ruud Dobber
    Executive Vice President - BioPharmaceuticals Business Unit
  • David Fredrickson
    Executive Vice President - Oncology Business Unit
  • Susan Galbraith
    Executive Vice President - Oncology and Research and Development
  • Menelas Pangalos
    Executive Vice President - Research and Development BioPharmaceuticals

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.